Butyrate in pediatric sepsis-associated acute kidney injury: the gut-kidney axis

Butyrate in pediatric sepsis-associated acute kidney injury: the gut-kidney axis

Paediatrics

Sepsis is a life-threatening condition characterised by organ dysfunction resulting from a dysregulated host response to infection. In critically ill children, sepsis-associated acute kidney injury (SA-AKI) is a serious complication linked to increased morbidity, prolonged intensive care unit stays, and adverse clinical outcomes. Emerging evidence highlights the role of the gut-kidney axis, a bidirectional interaction involving intestinal microbiota, microbial metabolites, immune regulation, and systemic inflammation, in the development of kidney injury during sepsis. Butyrate, a short-chain fatty acid (SCFA) produced through the bacterial fermentation of dietary fibres in the colon, has attracted interest because of its anti-inflammatory, immunomodulatory, and intestinal barrier-protective properties. Understanding its potential role in modulating the gut-kidney axis may provide insights into the mechanisms underlying paediatric SA-AKI, although its clinical application remains investigational.[1]Understanding the gut-kidney axis in sepsis-associated kidney injurySepsis can disrupt intestinal microbial composition, reduce beneficial commensal bacteria, and impair intestinal barrier functionIncreased intestinal permeability may facilitate the translocation of microbial products, including endotoxins, into the circulation, potentially amplifying systemic inflammationCirculating inflammatory mediators and microbial products can contribute to endothelial dysfunction, altered renal microcirculation, oxidative stress, and tubular injuryKidney dysfunction can further influence intestinal homeostasis through metabolic disturbances, inflammation, and changes in circulating uremic solutes, reinforcing the bidirectional gut-kidney interactionButyrate production and biological functionsButyrate is primarily generated through anaerobic fermentation of nondigestible carbohydrates by intestinal bacteriaIt serves as an important energy source for colonocytes and supports intestinal epithelial integrity and tight-junction functionButyrate also regulates immune activity through mechanisms involving histone deacetylase inhibition and G-protein-coupled receptor signalingThese actions may influence inflammatory cytokine production, immune-cell activity, and oxidative stress, potentially modifying the systemic inflammatory response associated with sepsisPotential renoprotective mechanisms of butyrateButyrate may help preserve intestinal barrier integrity, thereby limiting the entry of inflammatory microbial products into the systemic circulationIts immunomodulatory effects may reduce excessive inflammatory signaling, which contributes to endothelial and tubular injury during sepsisExperimental evidence suggests that butyrate may influence oxidative stress pathways and cellular responses involved in renal inflammationButyrate may also support mitochondrial function and cellular energy regulation, although the relevance of these effects to pediatric SA-AKI requires further investigationThrough interactions between the intestinal microbiota, immune system, and renal tissues, butyrate may help maintain gut-kidney homeostasis during systemic infectionClinical considerations in pediatric sepsis-associated acute kidney injuryThe potential therapeutic relevance of butyrate should be considered within the broader management of sepsis and kidney injury rather than as an established treatmentNutritional strategies that support intestinal microbial diversity and provide fermentable dietary substrates may influence endogenous SCFA productionHowever, critically ill children may have altered gastrointestinal function, feeding intolerance, and variable microbiome composition, which can affect butyrate production and availabilityThere is currently insufficient clinical evidence to establish the efficacy, optimal formulation, dose, timing, or safety of direct butyrate supplementation in children with SA-AKIResearch priorities and potential clinical applicationsFuture pediatric studies should investigate whether circulating and fecal butyrate concentrations correlate with AKI development, severity, and recoveryResearch should also evaluate whether changes in butyrate-producing bacterial populations are associated with intestinal barrier dysfunction and systemic inflammatory responsesExperimental investigations may help clarify the molecular pathways through which butyrate influences renal tubular inflammation, oxidative stress, and mitochondrial functionClinical trials are needed before butyrate supplementation can be considered a therapeutic strategy in pediatric sepsisResearch parameterPotential clinical relevanceFecal short-chain fatty acid profileMay characterize intestinal microbial metabolic activity.Plasma butyrate concentrationMay help investigate systemic butyrate availability.Intestinal permeability markersMay provide insights into epithelial barrier disruption.Urinary kidney injury biomarkersMay help characterize tubular injury beyond conventional renal function measurements.Gut microbiome diversityMay identify microbial patterns associated with sepsis-related metabolic disturbances.ConclusionSA-AKI is a common and serious complication of sepsis, contributing substantially to morbidity in critically ill children. Emerging evidence highlights the role of gut microbiota and the gut-kidney axis in kidney injury through interactions involving intestinal barrier integrity, microbial metabolites, and systemic inflammatory responses. Butyrate represents a promising area of investigation because of its potential to maintain intestinal barrier function, regulate inflammation, and modulate pathways involved in renal injury. However, its protective effects and therapeutic relevance in paediatric SA-AKI remain insufficiently established. Further mechanistic research and well-designed paediatric clinical studies are needed to clarify its role and evaluate its safety and potential application in the prevention or management of SA-AKI.[2]Reference(s):1. Liu Y, Liu Z, Xu H, et al. Butyrate mitigates multi-organ damage in urosepsis: associated changes in the renal NOX4/ROS/NF-κB axis and gut microbiota. Front Cell Infect Microbiol. 2026;16:1912506. Published 2026 Sep 1. doi:10.3389/fcimb.2026.1912506. https://pmc.ncbi.nlm.nih.gov/articles/PMC13574636/2. Xu Y, Kong X, Zhu Y, et al. Contribution of gut microbiota toward renal function in sepsis. Front Microbiol. 2022;13:985283. Published 2022 Sep 6. doi:10.3389/fmicb.2022.985283. https://pmc.ncbi.nlm.nih.gov/articles/PMC9486003/